Ocular Therapeutix, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bedford MA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2012
NCT01666210
First Marketed Drug
2018
urea
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ocular Therapeutix | OCULAR THERAPEUTIX | Ocular Therapeutix, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Capsule Opacification (Phase 3)

Cataract (Phase 4)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Dissociative Disorders (Phase 4)

Dry Eye Syndromes (Phase 4)

Eye Diseases (Phase 4)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Inflammation (Phase 4)

Iridocyclitis (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Keratoconus (Phase 4)

Macular Degeneration (Phase 4)

Macular Edema (Phase 4)

Ocular Hypertension (Phase 3)

Pain, Postoperative (Phase 4)

Pterygium (Phase 4)

Retinal Detachment (Phase 4)

Retinal Vein Occlusion (Phase 4)

Uveitis (Phase 4)

Uveitis, Anterior (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 15